Docetaxel plus oblimersen sodium (Bcl-2 antisense oligonucleotide): an EORTC multicenter, randomized phase II study in patients with castration-resistant _Drostate cancerSTERNBEG, C. N; DUMEZ, H; COLLETTE, L et al.Annals of oncology. 2009, Vol 20, Num 7, pp 1264-1269, issn 0923-7534, 6 p.Article

A randomized phase III study comparing standard dose BEP with sequential high-dose cisplatin, etoposide, and ifosfamide (VIP) plus stem-cell support in males with poor-prognosis germ-cell cancer. An intergroup study of EORTC, GTCSG, and Grupo Germinal (EORTC 30974)DAUGAARD, G; SKONECZNA, I; SCHMOLL, H. J et al.Annals of oncology. 2011, Vol 22, Num 5, pp 1054-1061, issn 0923-7534, 8 p.Article

A phase II multicentre study of irinotecan (CPT 11) in combination with cisplatin (CDDP) in metastatic or locally advanced penile carcinoma (EORTC PROTOCOL 30992)THEODORE, C; SKONECZNA, I; BODROGI, I et al.Annals of oncology. 2008, Vol 19, Num 7, pp 1304-1307, issn 0923-7534, 4 p.Article

Germ cell-like telomeric length homeostasis in nonseminomatous testicular germ cell tumorsNOWAK, R; SIKORA, K; PIETAS, A et al.Oncogene (Basingstoke). 2000, Vol 19, Num 35, pp 4075-4078, issn 0950-9232Article

A report comparing the use of tropisetron (Navoban), a 5-HT₃ antagonist, with a standard antiemetic regimen of dexamethasone and metoclopramide in cisplatin-treated patients under conditions of severe emesisMADEJ, G; KRZAKOWSKI, M; PAWINSKI, A et al.Seminars in oncology. 1994, Vol 21, Num 5, pp 3-6, issn 0093-7754, SUP9Conference Paper